Cargando…

Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer’s dementia

BACKGROUND: The progression of mild cognitive impairment (MCI) to Alzheimer’s disease (AD) dementia can be predicted by cognitive, neuroimaging, and cerebrospinal fluid (CSF) markers. Since most biomarkers reveal complementary information, a combination of biomarkers may increase the predictive powe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Frölich, Lutz, Peters, Oliver, Lewczuk, Piotr, Gruber, Oliver, Teipel, Stefan J., Gertz, Hermann J., Jahn, Holger, Jessen, Frank, Kurz, Alexander, Luckhaus, Christian, Hüll, Michael, Pantel, Johannes, Reischies, Friedel M., Schröder, Johannes, Wagner, Michael, Rienhoff, Otto, Wolf, Stefanie, Bauer, Chris, Schuchhardt, Johannes, Heuser, Isabella, Rüther, Eckart, Henn, Fritz, Maier, Wolfgang, Wiltfang, Jens, Kornhuber, Johannes
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5634868/ https://www.ncbi.nlm.nih.gov/pubmed/29017593 http://dx.doi.org/10.1186/s13195-017-0301-7

Ejemplares similares

Memory Concerns, Memory Performance and Risk of Dementia in Patients with Mild Cognitive Impairment
por: Wolfsgruber, Steffen, et al.
Publicado: (2014)

Apolipoprotein E-dependent load of white matter hyperintensities in Alzheimer’s disease: a voxel-based lesion mapping study
por: Morgen, Katrin, et al.
Publicado: (2015)

Don’t forget about tau: the effects of ApoE4 genotype on Alzheimer’s disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairment—data from the Dementia Competence Network
por: Benson, Gloria S., et al.
Publicado: (2022)

Combined treatment with memantine and galantamine-CR compared with galantamine-CR only in antidementia drug naïve patients with mild-to-moderate Alzheimer's disease
por: Peters, Oliver, et al.
Publicado: (2015)

A Comparison of Operational Definitions for Mild Cognitive Impairment
por: Polcher, Alexandra, et al.
Publicado: (2022)

Identification of a Cascade of Changes in Activities of Daily Living Preceding Short-Term Clinical Deterioration in Mild Alzheimer’s Disease Dementia via Lead-Lag Analysis
por: Fuentes, Manuel, et al.
Publicado: (2020)

Distributions of Aβ42 and Aβ42/40 in the Cerebrospinal Fluid in View of the Probability Theory
por: Lewczuk, Piotr, et al.
Publicado: (2021)

Is plasma amyloid-β 1–42/1–40 a better biomarker for Alzheimer’s disease than AβX–42/X–40?
por: Klafki, Hans-Wolfgang, et al.
Publicado: (2022)

CSF amyloid-β-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia
por: Bibl, Mirko, et al.
Publicado: (2006)

Combined Analysis of CSF Tau, Aβ42, Aβ1–42% and Aβ1–40(ox)% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia
por: Bibl, Mirko, et al.
Publicado: (2010)

Phagocytosis and LPS alter the maturation state of β-amyloid precursor protein and induce different Aβ peptide release signatures in human mononuclear phagocytes
por: Spitzer, Philipp, et al.
Publicado: (2010)

The Role of Cathepsin B in the Degradation of Aβ and in the Production of Aβ Peptides Starting With Ala2 in Cultured Astrocytes
por: Oberstein, Timo Jan, et al.
Publicado: (2021)

Clinical significance of fluid biomarkers in Alzheimer’s Disease
por: Lewczuk, Piotr, et al.
Publicado: (2020)

A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer’s disease
por: Shahpasand-Kroner, Hedieh, et al.
Publicado: (2018)

Cellular Receptors of Amyloid β Oligomers (AβOs) in Alzheimer’s Disease
por: Mroczko, Barbara, et al.
Publicado: (2018)

Alzheimer’s Disease—Biochemical and Psychological Background for Diagnosis and Treatment
por: Beata, Bocwinska-Kiluk, et al.
Publicado: (2023)

Key components and IT assistance of participant management in clinical research: a scoping review
por: Pung, Johannes, et al.
Publicado: (2020)

Analysis of Surface Levels of IL-1 Receptors and Macrophage Scavenger Receptor I in Peripheral Immune Cells of Patients With Alzheimer Disease
por: Spitzer, Philipp, et al.
Publicado: (2019)

Biomarkers for the Diagnosis of Alzheimer’s Disease in Clinical Practice: The Role of CSF Biomarkers during the Evolution of Diagnostic Criteria
por: Dulewicz, Maciej, et al.
Publicado: (2022)

Specific serum and CSF microRNA profiles distinguish sporadic behavioural variant of frontotemporal dementia compared with Alzheimer patients and cognitively healthy controls
por: Denk, Johannes, et al.
Publicado: (2018)

The Action of Key Factors in Protein Evolution at High Temporal Resolution
por: Schmitt, Armin, et al.
Publicado: (2009)

Bupropion for the Treatment of Apathy in Alzheimer Disease: A Randomized Clinical Trial
por: Maier, Franziska, et al.
Publicado: (2020)

Surface Trafficking of APP and BACE in Live Cells
por: Bauereiss, Anna, et al.
Publicado: (2015)

Perfusion Imaging with SPECT in the Era of Pathophysiology-Based Biomarkers for Alzheimer's Disease
por: Weih, Markus, et al.
Publicado: (2010)

Reconceptualization of the Erlangen Score for the Assessment of Dementia Risk: The ERlangen Score
por: Utz, Janine, et al.
Publicado: (2023)

Common strength and localization of spontaneous and evoked synaptic vesicle release sites
por: Loy, Kristina, et al.
Publicado: (2014)

Cognitive profiles of patients with mild cognitive impairment due to Alzheimer's versus Parkinson's disease defined using a base rate approach: Implications for neuropsychological assessments
por: Ophey, Anja, et al.
Publicado: (2021)

Digit ratio (2D:4D) and academic success as measured by achievement in the academic degree “Habilitation”
por: Tektas, Ozan Yüksel, et al.
Publicado: (2019)

Cerebrospinal fluid α synuclein concentrations in patients with positive AD biomarkers and extrapyramidal symptoms
por: Winkel, Izabela, et al.
Publicado: (2021)

Cerebrospinal Fluid Cortisol and Dehydroepiandrosterone Sulfate, Alzheimer’s Disease Pathology, and Cognitive Decline
por: Ouanes, Sami, et al.
Publicado: (2022)

Gesundheitliche Risiken von Einsamkeit und sozialer Isolation im Alter
por: Pantel, Johannes
Publicado: (2021)

Characterization of Acid Sphingomyelinase Activity in Human Cerebrospinal Fluid
por: Mühle, Christiane, et al.
Publicado: (2013)

Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer’s disease
por: Baldeiras, Inês, et al.
Publicado: (2019)

Feynman integrals in QCD made simple
por: Henn, Johannes
Publicado: (2015)

Substrate-Dependent Inhibition of the Human Organic Cation Transporter OCT2: A Comparison of Metformin with Experimental Substrates
por: Hacker, Kristina, et al.
Publicado: (2015)

Evidence for Elevated Cerebrospinal Fluid ERK1/2 Levels in Alzheimer Dementia
por: Spitzer, Philipp, et al.
Publicado: (2011)

Short Communication: Interaction of Nerve Growth Factor (NGF) and Vascular Endothelial Growth Factor (VEGF) in Healthy Individuals
por: Groh, Adrian, et al.
Publicado: (2019)

CSF nonphosphorylated Tau as a biomarker for the discrimination of AD from CJD
por: Ermann, Natalia, et al.
Publicado: (2018)

Effect of Minocycline on Depressive Symptoms in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial
por: Hellmann-Regen, Julian, et al.
Publicado: (2022)

Cross-national gender variations of digit ratio (2D:4D) correlate with life expectancy, suicide rate, and other causes of death
por: Lenz, Bernd, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_apmrp3cgqum2cdtr1s07rkqlqd